Abbvie received approval from the Food and Drug Administration for its drug treating people with a rare form of blood cancer. Decnupaz was approved to treat adults with Blastic Plasmacytoid Dendritic ...
(Corrects to clarify the total number of patients in the study in paragraph 10) May 27 (Reuters) - The U.S. Food and Drug ...
AbbVie (NYSE: ABBV) today announced that the U.S. Food and Drug Administration (FDA) has approved DECNUPAZTM (pivekimab sunirine-pvzy) for the treatment of adult patients with BPDCN, an ultra-rare and ...
Stocktwits on MSN
ABBV stock gains on winning FDA approval for rare blood cancer drug
The drug is specifically approved to treat blastic plasmacytoid dendritic cell neoplasm (an ultra-rare and aggressive type of ...
The FDA approved the antibody-drug conjugate pivekimab sunirine (Decnupaz) for the rare hematologic malignancy blastic ...
A blastic plasmacytoid dendritic-cell neoplasm is a rare tumor with very aggressive clinical behavior and no established treatment. 1 Available treatment options include aggressive multiagent ...
Please provide your email address to receive an email when new articles are posted on . The FDA granted breakthrough therapy designation to IMGN632 for treatment of relapsed or refractory blastic ...
Is the Fixed-Dose Intravenous Trastuzumab Policy Warranted in Limited-Resource Settings? A 29-year-old woman presented with a 2-year history of a slow-growing, indurated, and ulcerated skin mass at ...
Jodi Karnell and colleagues have developed a monoclonal antibody, VIB7734, that reduces symptom severity in people with cutaneous lupus by targeting and depleting plasmacytoid dendritic cells (pDC) in ...
A recent research paper by scientists from Denmark reveals that circulating plasmacytoid dendritic cells may be a potential therapeutic target to maintain desired levels of an antiviral compound known ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results